3 Stocks to Avoid This Week

Motley Fool2022-10-25

Wall Street bounced back in a major way last week. The "three stocks to avoid" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

362

Report

Comment（93）

WeeLee
·2022-10-25
Like
Reply
1
Report
MrHuattt
·2022-10-25
Ok
Reply
1
Report
Fold Replies
- MrHuattt:
  Sure
  2022-10-25
  Reply
  Report
bwjx
·2022-10-25
See how the market react to earnings. Withhold all judgements for now. [Happy]
Reply
4
Report
yyhwin
·2022-10-25
Hi
Reply
3
Report
vxf
·2022-10-25
Stay
Reply
4
Report
Le66ad
·2022-10-25
👍🏻
Reply
5
Report
Fold Replies
- Dividend Investing:
  Ok
  2022-10-25
  Reply
  Report
- Le66ad:
  👍🏻
  2022-10-25
  Reply
  Report
Tomatoto
·2022-10-25
Like
Reply
2
Report
Fold Replies
- KennethM:
  Ok
  2022-10-25
  Reply
  Report
ChrisLiew
·2022-10-25
Like pls
Reply
6
Report
chai88
·2022-10-25
Ok
Reply
2
Report
Singmeamelodyy
·2022-10-25
K
Reply
6
Report
Fold Replies
- ChrisLiew:
  ok
  2022-10-25
  Reply
  Report
CindyKwa
·2022-10-25
Will stay away ...
Reply
3
Report
Fold Replies
- yyhwin:
  Hi
  2022-10-25
  Reply
  Report
- vxf:
  the
  2022-10-25
  Reply
  Report
Bonghanhuei
·2022-10-25
Ok
Reply
7
Report
Fold Replies
- Tomatoto:
  Ok
  2022-10-25
  Reply
  Report
- Taufiq:
  ok
  2022-10-25
  Reply
  Report
SallyNeo
·2022-10-25
Ok
Reply
4
Report
Fold Replies
- SallyNeo:
  Ok
  2022-10-25
  Reply
  Report
JeffTai
·2022-10-25
Ok
Reply
8
Report
Fold Replies
- BenYSLim:
  Ok
  2022-10-25
  Reply
  Report
Andrewinho
·2022-10-25
Really? 🤔🤔🤔
Reply
6
Report
weekendnote
·2022-10-25
Ok
Reply
8
Report
Fold Replies
- Yappy:
  ok
  2022-10-25
  Reply
  Report
naf
·2022-10-25
K
Reply
8
Report
Fold Replies
- Tj23:
  Ok
  2022-10-25
  Reply
  Report
- Bonghanhuei:
  ok
  2022-10-25
  Reply
  Report
- naf:
  k
  2022-10-25
  Reply
  Report
MichT
·2022-10-25
Thanks
Reply
7
Report
Fold Replies
- JeffTai:
  ok
  2022-10-25
  Reply
  Report
- weekendnote:
  ok
  2022-10-25
  Reply
  Report
TigerHulk
·2022-10-25
Why never add in Meta?
Reply
1
Report
LEESIMON
·2022-10-25
OK
Reply
7
Report
Fold Replies
- skylander:
  wow
  2022-10-25
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2277277881?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-10-25 11:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2277277881","market":"us","top_or_hot":-1,"title":"3 Stocks to Avoid This Week","media":"Motley Fool","content":"<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMZN","symbol_name":"亚马逊","start_time":0,"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","article_id":"2277277881","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","pubTimestamp":1666669590,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These investments seem pretty vulnerable right now.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"translate_title":"本周要回避的3只股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"AMZN":0.9,"OSTK":0.9},"content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9988370551,"gmtCreate":1666677249273,"gmtModify":1676537788506,"author":{"id":"3568016139154441","authorId":"3568016139154441","name":"WeeLee","avatar":"https://community-static.tradeup.com/news/ece9747089f75a8bbd4983d0e64c460d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3568016139154441","authorIdStr":"3568016139154441"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988370551","repostId":2277277881,"repostType":2,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9988342438,"gmtCreate":1666676123324,"gmtModify":1676537788268,"author":{"id":"4089116574465250","authorId":"4089116574465250","name":"MrHuattt","avatar":"https://community-static.tradeup.com/news/e67f8f8c2b0192fadc4cd499a84e6c8b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"4089116574465250","authorIdStr":"4089116574465250"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9988342438","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500980,"gmtCreate":1666676128617,"gmtModify":1666676132437,"authorId":4089116574465250,"author":{"id":4089116574465250,"idStr":"4089116574465250","authorId":4089116574465250,"name":"MrHuattt","avatar":"https://community-static.tradeup.com/news/e67f8f8c2b0192fadc4cd499a84e6c8b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988342438,"type":1,"supId":0,"prevId":0,"content":"<u>Sure</u>","text":"<u>Sure</u>","html":"<u>Sure</u>"}],"langContent":"EN"},{"id":9988342220,"gmtCreate":1666676086360,"gmtModify":1676537788262,"author":{"id":"3583219343417269","authorId":"3583219343417269","name":"bwjx","avatar":"https://community-static.tradeup.com/news/8caef76a71a3e44507b696f3580a8fd7","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583219343417269","authorIdStr":"3583219343417269"},"htmlText":"See how the market react to earnings. Withhold all judgements for now.&nbsp;[Happy]&nbsp;","listText":"See how the market react to earnings. Withhold all judgements for now.&nbsp;[Happy]&nbsp;","text":"See how the market react to earnings. Withhold all judgements for now. [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988342220","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9988343616,"gmtCreate":1666675158035,"gmtModify":1676537788134,"author":{"id":"3581931076615563","authorId":"3581931076615563","name":"yyhwin","avatar":"https://static.tigerbbs.com/78727032603c2751ac0b6b6cfb678920","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3581931076615563","authorIdStr":"3581931076615563"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988343616","repostId":2277277881,"repostType":2,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9988343320,"gmtCreate":1666675134660,"gmtModify":1676537788126,"author":{"id":"3582839637303229","authorId":"3582839637303229","name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582839637303229","authorIdStr":"3582839637303229"},"htmlText":"Stay","listText":"Stay","text":"Stay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988343320","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9988349723,"gmtCreate":1666675123363,"gmtModify":1676537788119,"author":{"id":"3569206984348246","authorId":"3569206984348246","name":"Le66ad","avatar":"https://static.tigerbbs.com/6c476ea553750ec9e5c4f1d349e84eb2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3569206984348246","authorIdStr":"3569206984348246"},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9988349723","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500826,"gmtCreate":1666675376214,"gmtModify":1666675379719,"authorId":3582028836908731,"author":{"id":3582028836908731,"idStr":"3582028836908731","authorId":3582028836908731,"name":"Dividend Investing","avatar":"https://community-static.tradeup.com/news/81d67c4340846e48f7d51d130e813138","vip":1,"currentWearingBadge":{"badgeId":"23f878ed27704312ae41c7f17e73b319-4","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 10%","bigImgUrl":"https://community-static.tradeup.com/news/15d4b5a89fa218ed3a35da1a05874cf6","smallImgUrl":"https://community-static.tradeup.com/news/16e2b28d75d7746886400fad4f4ec3e3","grayImgUrl":"https://community-static.tradeup.com/news/6f578d36f80e1a3d9c705f395e522048","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.31","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5300},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988349723,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":104500751,"gmtCreate":1666675131412,"gmtModify":1666675135123,"authorId":3569206984348246,"author":{"id":3569206984348246,"idStr":"3569206984348246","authorId":3569206984348246,"name":"Le66ad","avatar":"https://static.tigerbbs.com/6c476ea553750ec9e5c4f1d349e84eb2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988349723,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">👍🏻</span>","text":"<span class=\"s1\">👍🏻</span>","html":"<span class=\"s1\">👍🏻</span>"}],"langContent":"EN"},{"id":9988349578,"gmtCreate":1666675048494,"gmtModify":1676537788111,"author":{"id":"4098449423449400","authorId":"4098449423449400","name":"Tomatoto","avatar":"https://static.tigerbbs.com/ae6d0aaaafd447ed7c5dc016515242d8","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4098449423449400","authorIdStr":"4098449423449400"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9988349578","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500863,"gmtCreate":1666675524526,"gmtModify":1666675528045,"authorId":3568326695373786,"author":{"id":3568326695373786,"idStr":"3568326695373786","authorId":3568326695373786,"name":"KennethM","avatar":"https://static.tigerbbs.com/b5c1d63e5cb5064f84c7251e09ad63e7","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988349578,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9988349951,"gmtCreate":1666674905473,"gmtModify":1676537788095,"author":{"id":"3580393689769738","authorId":"3580393689769738","name":"ChrisLiew","avatar":"https://static.tigerbbs.com/35b3b9b772013ce79f9f4c5318d46fa7","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":1,"idStr":"3580393689769738","authorIdStr":"3580393689769738"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988349951","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9988340546,"gmtCreate":1666674834785,"gmtModify":1676537788087,"author":{"id":"3583047307109635","authorId":"3583047307109635","name":"chai88","avatar":"https://community-static.tradeup.com/news/58cd61c87afd62ee9ae91c7ec7707f45","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3583047307109635","authorIdStr":"3583047307109635"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988340546","repostId":2277277881,"repostType":2,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9988340943,"gmtCreate":1666674764182,"gmtModify":1676537788072,"author":{"id":"4112236528991632","authorId":"4112236528991632","name":"Singmeamelodyy","avatar":"https://community-static.tradeup.com/news/bd6f4b2042c573a893dce45a93a107fb","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4112236528991632","authorIdStr":"4112236528991632"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9988340943","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500714,"gmtCreate":1666674911200,"gmtModify":1666674914814,"authorId":3580393689769738,"author":{"id":3580393689769738,"idStr":"3580393689769738","authorId":3580393689769738,"name":"ChrisLiew","avatar":"https://static.tigerbbs.com/35b3b9b772013ce79f9f4c5318d46fa7","vip":1,"currentWearingBadge":{"badgeId":"82ffa69a97264fba9002044f4f5f535b-1","templateUuid":"82ffa69a97264fba9002044f4f5f535b","name":"Tiger Think Tank","description":"Tiger Think Tank","bigImgUrl":"https://community-static.tradeup.com/news/193f8255673f42bdc610097b2074ec3e","smallImgUrl":"https://community-static.tradeup.com/news/06af124f59f026a383d35b268362424f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.06","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":4001},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988340943,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9988358790,"gmtCreate":1666673876510,"gmtModify":1676537787923,"author":{"id":"4126410408764842","authorId":"4126410408764842","name":"CindyKwa","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4126410408764842","authorIdStr":"4126410408764842"},"htmlText":"Will stay away ...","listText":"Will stay away ...","text":"Will stay away ...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9988358790","repostId":2277277881,"repostType":2,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500765,"gmtCreate":1666675204365,"gmtModify":1666675207734,"authorId":3581931076615563,"author":{"id":3581931076615563,"idStr":"3581931076615563","authorId":3581931076615563,"name":"yyhwin","avatar":"https://static.tigerbbs.com/78727032603c2751ac0b6b6cfb678920","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988358790,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Hi</span>","text":"<span class=\"s1\">Hi</span>","html":"<span class=\"s1\">Hi</span>"},{"id":104500759,"gmtCreate":1666675150889,"gmtModify":1666675154173,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988358790,"type":1,"supId":0,"prevId":0,"content":"<u>the</u>","text":"<u>the</u>","html":"<u>the</u>"}],"langContent":"EN"},{"id":9988351349,"gmtCreate":1666673199382,"gmtModify":1676537787865,"author":{"id":"3581734044994294","authorId":"3581734044994294","name":"Bonghanhuei","avatar":"https://static.tigerbbs.com/c688d7ad40c511adab3aa29cdc4befc5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581734044994294","authorIdStr":"3581734044994294"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9988351349","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500732,"gmtCreate":1666675043618,"gmtModify":1666675047045,"authorId":4098449423449400,"author":{"id":4098449423449400,"idStr":"4098449423449400","authorId":4098449423449400,"name":"Tomatoto","avatar":"https://static.tigerbbs.com/ae6d0aaaafd447ed7c5dc016515242d8","vip":1,"currentWearingBadge":{"badgeId":"23f878ed27704312ae41c7f17e73b319-2","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 30%","bigImgUrl":"https://community-static.tradeup.com/news/50461c8139b6ca50fe2dae19aa769b25","smallImgUrl":"https://community-static.tradeup.com/news/c8eef504853d5a517c50d7a88fa5c1e1","grayImgUrl":"https://community-static.tradeup.com/news/5273727845028b8d9b65556bdcb217b9","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.20","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5300},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988351349,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":104500516,"gmtCreate":1666674247679,"gmtModify":1666674250912,"authorId":3577780267544506,"author":{"id":3577780267544506,"idStr":"3577780267544506","authorId":3577780267544506,"name":"Taufiq","avatar":"https://static.tigerbbs.com/b73c6ffb978f4a6adc4a6b57c9578f5b","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988351349,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9988353600,"gmtCreate":1666673074500,"gmtModify":1676537787832,"author":{"id":"3569657483407888","authorId":"3569657483407888","name":"SallyNeo","avatar":"https://static.tigerbbs.com/36144116caeba1af1d2ccbebeffac342","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569657483407888","authorIdStr":"3569657483407888"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9988353600","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500146,"gmtCreate":1666673090726,"gmtModify":1666673094434,"authorId":3569657483407888,"author":{"id":3569657483407888,"idStr":"3569657483407888","authorId":3569657483407888,"name":"SallyNeo","avatar":"https://static.tigerbbs.com/36144116caeba1af1d2ccbebeffac342","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988353600,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9988359630,"gmtCreate":1666672838321,"gmtModify":1676537787766,"author":{"id":"3581504334066898","authorId":"3581504334066898","name":"JeffTai","avatar":"https://static.tigerbbs.com/eaf357935d6e8ef3744f3d94312f0a64","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581504334066898","authorIdStr":"3581504334066898"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9988359630","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500313,"gmtCreate":1666673640588,"gmtModify":1666673643741,"authorId":3584102971420376,"author":{"id":3584102971420376,"idStr":"3584102971420376","authorId":3584102971420376,"name":"BenYSLim","avatar":"https://static.tigerbbs.com/94898501beebba354d54215388e5f9d1","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988359630,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9988327706,"gmtCreate":1666672451006,"gmtModify":1676537787718,"author":{"id":"3581563418944392","authorId":"3581563418944392","name":"Andrewinho","avatar":"https://static.tigerbbs.com/3127e2bc40ab23064a5187a00a63e19b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581563418944392","authorIdStr":"3581563418944392"},"htmlText":"Really? 🤔🤔🤔","listText":"Really? 🤔🤔🤔","text":"Really? 🤔🤔🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988327706","repostId":2277277881,"repostType":2,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9988325983,"gmtCreate":1666671822042,"gmtModify":1676537787628,"author":{"id":"3555200317437246","authorId":"3555200317437246","name":"weekendnote","avatar":"https://community-static.tradeup.com/news/d60a8ac425f5151e5bcdc426262fb043","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3555200317437246","authorIdStr":"3555200317437246"},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9988325983","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500917,"gmtCreate":1666675864469,"gmtModify":1666675867835,"authorId":3572077804076143,"author":{"id":3572077804076143,"idStr":"3572077804076143","authorId":3572077804076143,"name":"Yappy","avatar":"https://static.tigerbbs.com/ab4d89913ade03f15c782b99132ba22f","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.18%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988325983,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9988322862,"gmtCreate":1666671725656,"gmtModify":1676537787610,"author":{"id":"3584567729657839","authorId":"3584567729657839","name":"naf","avatar":"https://static.tigerbbs.com/901464b7f838cff158663fe74b06d9e2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3584567729657839","authorIdStr":"3584567729657839"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9988322862","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500514,"gmtCreate":1666674231078,"gmtModify":1666674238999,"authorId":3571780042589602,"author":{"id":3571780042589602,"idStr":"3571780042589602","authorId":3571780042589602,"name":"Tj23","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988322862,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":104500185,"gmtCreate":1666673207939,"gmtModify":1666673211546,"authorId":3581734044994294,"author":{"id":3581734044994294,"idStr":"3581734044994294","authorId":3581734044994294,"name":"Bonghanhuei","avatar":"https://static.tigerbbs.com/c688d7ad40c511adab3aa29cdc4befc5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988322862,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":104499738,"gmtCreate":1666671731807,"gmtModify":1666671735092,"authorId":3584567729657839,"author":{"id":3584567729657839,"idStr":"3584567729657839","authorId":3584567729657839,"name":"naf","avatar":"https://static.tigerbbs.com/901464b7f838cff158663fe74b06d9e2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988322862,"type":1,"supId":0,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"}],"langContent":"EN"},{"id":9988328120,"gmtCreate":1666671429161,"gmtModify":1676537787552,"author":{"id":"4101198001266260","authorId":"4101198001266260","name":"MichT","avatar":"https://static.tigerbbs.com/77f87c46e06ac2aee91bc63f1a527221","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4101198001266260","authorIdStr":"4101198001266260"},"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9988328120","repostId":2277277881,"repostType":2,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500082,"gmtCreate":1666672850277,"gmtModify":1666672853863,"authorId":3581504334066898,"author":{"id":3581504334066898,"idStr":"3581504334066898","authorId":3581504334066898,"name":"JeffTai","avatar":"https://static.tigerbbs.com/eaf357935d6e8ef3744f3d94312f0a64","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988328120,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":104499785,"gmtCreate":1666671831526,"gmtModify":1666671835631,"authorId":3555200317437246,"author":{"id":3555200317437246,"idStr":"3555200317437246","authorId":3555200317437246,"name":"weekendnote","avatar":"https://community-static.tradeup.com/news/d60a8ac425f5151e5bcdc426262fb043","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988328120,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":9988321479,"gmtCreate":1666671345291,"gmtModify":1676537787529,"author":{"id":"4111448269923362","authorId":"4111448269923362","name":"TigerHulk","avatar":"https://community-static.tradeup.com/news/9e1491ac4fc7b7459eacd64c6be410ae","vip":2,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":7,"crmLevelSwitch":1,"idStr":"4111448269923362","authorIdStr":"4111448269923362"},"htmlText":"Why never add in Meta?","listText":"Why never add in Meta?","text":"Why never add in Meta?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988321479","repostId":2277277881,"repostType":2,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9988323893,"gmtCreate":1666671122413,"gmtModify":1676537787496,"author":{"id":"3579044609497336","authorId":"3579044609497336","name":"LEESIMON","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"3579044609497336","authorIdStr":"3579044609497336"},"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9988323893","repostId":2277277881,"repostType":4,"repost":{"id":"2277277881","pubTimestamp":1666669590,"share":"https://ttm.financial/m/news/2277277881?lang=&edition=fundamental","pubTime":"2022-10-25 11:46","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2277277881","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Wall Street bounced back in a major way last week. The &#34;three stocks to avoid&#34; in my column last week that I thought were going to lose to the market -- <b>Snap</b>, <b>Freeport-McMoran</b>, and <b>Gold Fields</b> -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.</p><p>The <b>S&amp;P 500</b> experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Amazon.com</b>, <b>AbbVie</b>, and, <b><a href=\"https://laohu8.com/S/OSTK\">Overstock.com</a></b>as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Amazon</b></h2><p>I thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon&#39;s earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week&#39;s report, but margins are probably still contracting.</p><p>&#34;Your margin is my opportunity&#34; is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn&#39;t get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.</p><p>I&#39;m an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.</p><h2><b>2. AbbVie</b></h2><p>Investors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.</p><p>AbbVie may seem to be an odd name on this list, but let&#39;s talk about reality. The near-term outlook is hazy here. It&#39;s best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There&#39;s also no denying that the U.S. government is pushing hard to keep drug prices in low.</p><p>AbbVie does have some young drugs that will help some of the sting of Humira&#39;s coming competition from the generics market. But it won&#39;t be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.</p><h2><b>3. Overstock.com</b></h2><p>If I&#39;m putting Amazon on this list, I may as well single out an online retailer that&#39;s faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we&#39;ve seen four consecutive quarters of year-over-year declines at this deep discounter.</p><p>You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn&#39;t been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Amazon.com, AbbVie, and Overstock.com this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2277277881","content_text":"Wall Street bounced back in a major way last week. The \"three stocks to avoid\" in my column last week that I thought were going to lose to the market -- Snap, Freeport-McMoran, and Gold Fields -- plummeted 22%, soared 16%, and rose 6% fell, respectively, averaging out to a flat 0% move.The S&P 500 experienced a 4.7% move higher. I was correct. I have been right in 34 of the past 53 weeks, or 64% of the time.Now let's look at the week ahead. I see Amazon.com, AbbVie, and, Overstock.comas stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. AmazonI thought I would never see the day when the mighty Amazon makes the cut on this list, but here we are. Amazon has struggled heading into Thursday afternoon's earnings report. The online retailing bellwether has surprised investors with back-to-back quarterly losses. Revenue growth has decelerated sharply for five consecutive quarters. Sales should pick back up with this week's report, but margins are probably still contracting.\"Your margin is my opportunity\" is one of the most famous quotes by Amazon founder and former CEO Jeff Bezos. Can the e-tailer afford to ignore its meager markups? A lot of costs are rising at Amazon, and it probably didn't get a break this summer. The holidays are coming, but consumers are likely to hold their pocketbooks tighter than usual in this iffy economic climate.I'm an Amazon shareholder, but I have my concerns. Prove me wrong, Amazon.2. AbbVieInvestors see profitable drug companies as all-weather performers, and AbbVie packs healthy earnings with a chunky 3.8% yield. It reports quarterly results near the end of the week, and analysts are eyeing decent growth on both ends of the income statement.AbbVie may seem to be an odd name on this list, but let's talk about reality. The near-term outlook is hazy here. It's best-selling drug, Humira, goes off patent next year, and Wall Street pros see sales sliding 7% next year -- with an even bigger decline on the bottom line. There's also no denying that the U.S. government is pushing hard to keep drug prices in low.AbbVie does have some young drugs that will help some of the sting of Humira's coming competition from the generics market. But it won't be enough. And the company would be doing its shareholders a disservice if it offers a rosy outlook on Friday morning.3. Overstock.comIf I'm putting Amazon on this list, I may as well single out an online retailer that's faring even worse. Overstock.com is in a world of hurt. Sales may be slowing at Amazon, but we've seen four consecutive quarters of year-over-year declines at this deep discounter.You would think a potential recessionary environment would be a dinner bell for a company selling clearance, distressed, and overstock items at bargain prices, but that hasn't been the case. Like the merchandise it sells, Overstock shares and profit targets are falling. It joins Amazon and AbbVie in reporting fresh financials this week, and this one could be the scariest of the three reports.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Amazon.com, AbbVie, and Overstock.com this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104499655,"gmtCreate":1666671467617,"gmtModify":1666671471497,"authorId":4087989241523320,"author":{"id":4087989241523320,"idStr":"4087989241523320","authorId":4087989241523320,"name":"skylander","avatar":"https://static.tigerbbs.com/1c70a5b34449eb6137e74ae1fefb2ea0","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988323893,"type":1,"supId":0,"prevId":0,"content":"wow","text":"wow","html":"wow"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":362,"commentSize":93,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false}}